DekaBank Deutsche Girozentrale Has $10.64 Million Stock Holdings in The Clorox Company (NYSE:CLX)

DekaBank Deutsche Girozentrale lifted its position in The Clorox Company (NYSE:CLX) by 11.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,890 shares of the company’s stock after acquiring an additional 7,995 shares during the period. DekaBank Deutsche Girozentrale owned approximately 0.06% of Clorox worth $10,635,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Nuance Investments LLC raised its position in shares of Clorox by 150.6% in the 2nd quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock valued at $218,035,000 after acquiring an additional 960,094 shares during the period. Oppenheimer & Co. Inc. increased its stake in Clorox by 4.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 17,042 shares of the company’s stock worth $2,326,000 after purchasing an additional 659 shares in the last quarter. Vest Financial LLC increased its stake in Clorox by 11.7% during the 2nd quarter. Vest Financial LLC now owns 301,741 shares of the company’s stock worth $41,179,000 after purchasing an additional 31,691 shares in the last quarter. Achmea Investment Management B.V. increased its stake in Clorox by 3.7% during the 2nd quarter. Achmea Investment Management B.V. now owns 33,538 shares of the company’s stock worth $4,577,000 after purchasing an additional 1,201 shares in the last quarter. Finally, Trifecta Capital Advisors LLC increased its stake in Clorox by 139.8% during the 2nd quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company’s stock worth $30,000 after purchasing an additional 130 shares in the last quarter. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Clorox

In other Clorox news, EVP Angela C. Hilt sold 1,733 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $165.52, for a total transaction of $286,846.16. Following the completion of the sale, the executive vice president now owns 13,471 shares of the company’s stock, valued at approximately $2,229,719.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.51% of the company’s stock.

Clorox Price Performance

NYSE:CLX opened at $165.95 on Tuesday. The Clorox Company has a 1-year low of $114.68 and a 1-year high of $169.09. The company has a current ratio of 1.03, a quick ratio of 0.63 and a debt-to-equity ratio of 5.04. The firm has a fifty day simple moving average of $146.82 and a 200 day simple moving average of $143.33. The stock has a market capitalization of $20.61 billion, a PE ratio of 85.98, a P/E/G ratio of 3.29 and a beta of 0.40.

Clorox (NYSE:CLX) last announced its quarterly earnings results on Thursday, August 1st. The company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.28. Clorox had a return on equity of 281.12% and a net margin of 3.95%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.97 billion. On average, research analysts expect that The Clorox Company will post 6.63 EPS for the current fiscal year.

Clorox Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Wednesday, August 14th were issued a dividend of $1.22 per share. This is an increase from Clorox’s previous quarterly dividend of $1.20. The ex-dividend date was Tuesday, August 13th. This represents a $4.88 annualized dividend and a yield of 2.94%. Clorox’s dividend payout ratio (DPR) is currently 252.85%.

Analyst Ratings Changes

A number of analysts recently issued reports on CLX shares. Barclays increased their target price on Clorox from $122.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Deutsche Bank Aktiengesellschaft increased their target price on Clorox from $144.00 to $151.00 and gave the stock a “hold” rating in a research note on Friday, August 2nd. TD Cowen began coverage on Clorox in a research note on Tuesday, July 23rd. They set a “sell” rating and a $122.00 target price for the company. Citigroup raised their price target on shares of Clorox from $165.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, September 6th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Clorox from $150.00 to $148.00 and set a “neutral” rating for the company in a research note on Friday, August 2nd. Six research analysts have rated the stock with a sell rating and thirteen have given a hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $143.50.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.